Evidence map›Paper›PMID 32769181›Full record

ArticleApplied and environmental microbiology2020

Genetic Reprogramming of the Ergot Alkaloid Pathway of Metarhizium brunneum.

Kyle A Davis, Jessi K Sampson, Daniel G Panaccione

Open access · greenAbstract read
In one paragraph

Article in Applied and environmental microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
7.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. A gene regulating ergot alkaloid biosynthesis inApplied and environmental microbiology · 2024
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Ergot Alkaloids Contribute to the Pathogenic Potential of the FungusApplied and environmental microbiology · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Construction of an efficientFrontiers in bioengineering and biotechnology · 2022
    Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Kyle A DavisWest Virginia University, Genetics and Developmental Biology Program, Division of Plant and Soil Sciences, Morgantown, West Virginia, USA.
Jessi K SampsonWest Virginia University, Genetics and Developmental Biology Program, Division of Plant and Soil Sciences, Morgantown, West Virginia, USA.
Daniel G PanaccioneWest Virginia University, Genetics and Developmental Biology Program, Division of Plant and Soil Sciences, Morgantown, West Virginia, USA danpan@wvu.edu.ORCID 0000-0002-4159-164X
West Virginia University · US

Funding

Strategic Reprogramming of the Ergot Alkaloid PathwayR15GM114774 · NIGMS · WEST VIRGINIA UNIVERSITY · PI PANACCIONE, DANIEL G. · 2015 to 2023
$1.3M
NIGMS NIH HHS R15 GM114774
6 · The paper itself

Abstract

Ergot alkaloids are important specialized fungal metabolites that are used to make potent pharmaceuticals for neurological diseases and disorders. Lysergic acid (LA) and dihydrolysergic acid (DHLA) are desirable lead compounds for pharmaceutical semisynthesis but are typically transient intermediates in the ergot alkaloid and dihydroergot alkaloid pathways. Previous work with

Indexed as

CRISPR-Cas SystemsErgot AlkaloidsMetabolic Networks and PathwaysMetarhiziumMicroorganisms, Genetically-ModifiedErgot Alkaloidsalkaloid secretiondihydroergot alkaloidsergot alkaloidslysergic acidMetarhizium

Identifiers

PMID32769181
PMCPMC7499049
OpenAlexW3046948483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.